Free Trial

Corvus Pharmaceuticals (CRVS) News Today

$2.04
-0.08 (-3.77%)
(As of 06/14/2024 ET)
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Drop in Short Interest
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) saw a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 1,290,000 shares, a drop of 5.1% from the April 30th total of 1,360,000 shares. Based on an average daily volume of 248,500 shares, the days-to-cover ratio is currently 5.2 days.
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Above 50 Day Moving Average of $1.77
Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Crosses Above 50-Day Moving Average of $1.77
13 Penny Stocks with Insider Buying in 2024
William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) insider William Benton Jones acquired 20,000 shares of the stock in a transaction dated Monday, May 6th. The shares were purchased at an average price of $1.73 per share, for a total transaction of $34,600.00. Following the completion of the transaction, the insider now owns 153,773 shares of the company's stock, valued at approximately $266,027.29. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Q1 2024 Corvus Pharmaceuticals Inc Earnings Call
Oppenheimer Increases Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target to $8.00
Oppenheimer upped their target price on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Tuesday.
Corvus Pharmaceuticals (CRVS) Set to Announce Earnings on Monday
Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings after the market closes on Monday, May 6, Zacks reports.
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 6.0% in March
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 1,400,000 shares, a decrease of 6.0% from the March 15th total of 1,490,000 shares. Currently, 3.8% of the shares of the stock are sold short. Based on an average trading volume of 212,900 shares, the days-to-cover ratio is currently 6.6 days.
Corvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.35) pe
Cantor Fitzgerald Reaffirms Overweight Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)
Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Corvus Pharmaceuticals in a research note on Monday.
Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)
Mizuho reaffirmed a "neutral" rating and set a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday.
Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Lowered to $7.00 at Oppenheimer
Oppenheimer cut their price target on Corvus Pharmaceuticals from $8.00 to $7.00 and set an "outperform" rating for the company in a research note on Wednesday.
Q4 2023 Corvus Pharmaceuticals Inc Earnings Call
Corvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Tuesday
Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings on Tuesday, March 19, Yahoo Finance reports.
CRVS Apr 2024 4.000 put
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 8.0% in February
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,270,000 shares, a decline of 8.0% from the January 31st total of 1,380,000 shares. Approximately 3.4% of the shares of the stock are short sold. Based on an average trading volume of 206,300 shares, the short-interest ratio is currently 6.2 days.
CRVS Mar 2024 3.000 put
Corvus Edges up on Disclosing Data
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
Corvus Pharmaceuticals Inc CRVS

CRVS Media Mentions By Week

CRVS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRVS
News Sentiment

0.44

0.90

Average
Medical
News Sentiment

CRVS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRVS Articles
This Week

2

1

CRVS Articles
Average Week

Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CRVS) was last updated on 6/15/2024 by MarketBeat.com Staff

From Our Partners